In recent years advances in protein engineering have allowed us to build antibody structures with two or more specificities- bispecific antibodies. At PEGS in Boston last month, our team presented a poster that demonstrated the development of high throughput screening for the purification of different bispecific formats. Three bispecific molecules against the same two targets were expressed in different formats that incorporated different molecular engineering strategies to achieve effective purification. Access the poster here: https://lnkd.in/gC3ZSRaP Abzena poster authors include: Beata Blaszczyk, Elizabeth Willows, Kalpana Wood, Prakash Nayee, Marina Leal, Bill McDowell, Nicole Wakes, Simon Keen,?and Rob Holgate #CDMO #CRO #bispecifics #drugdevelopment
Abzena的动态
最相关的动态
-
#LipidNanoparticles, #RNATherapeutics, #QualityAssessment | ?????? ???????????????? ???? ?????? ???????? ???? ???????????? ???????????????????? ?????????????? ???? ?????? ?????????????????????? ???? ???????????????????? ?????? ??????????????????? ?? ?????? To assess the quality of lipid nanoparticles (LNPs) used for in-vivo intracellular delivery of nucleic acids through comprehensive analytical methods. ?? ?????? ???????????????? Evaluation and comparison of analytical protocols for chemical composition, drug loading, particle size, concentration, and stability. Assessment of measurement protocols for reproducibility, robustness, and correlative approaches. ?? ???????? ???????? ?????????????? This research highlights the importance of detailed characterization strategies to support the quality assessment of RNA therapeutics. Check here for more: https://lnkd.in/ectX4Dic Thank you, Jérémie Parot, Dora Mehn, Hanna Jankevics Jones, Natalia Markova, Michele Carboni, Camilla Olaisen, Andrea Draget Hoel, Margret Asa Sigfusdottir, Florian Meier, Roland Drexel, Gabriele Vella, Birgitte Hjelmeland McDonagh, Hansen Terkel, Thanh-Huong Bui, Geir Klinkenberg, Torkild Visnes, sabrina gioria, Patricia Urban Lopez, Adriele Prina Mello, Sven Even F. Borgos, Luigi Calzolai.
-
-
What's better for Bioprocess manufacturing? -- Column Chromatography vs Magnetic Bead Separation -- Find out in the latest peer reviewed journal article: "Side-by-Side Economic Process Model for the Comparison and Evaluation of Magnetic Bead-Based Processes and Legacy Process for the Manufacturing of Monoclonal Antibodies,"?in?Processes MDPI This study explores a transformative approach to monoclonal antibody manufacturing. The findings reveal that?magnetic separation?economically outperforms traditional processes, paving the way for more efficient and sustainable biomanufacturing solutions. This work was accomplished by Nils Brechmann, Ph.D., Christos Stamatis, Suzanne Farid, Veronique Chotteau and Kristofer Eriksson. Check out the full paper here: https://lnkd.in/dZatEDQq #Biomanufacturing #MonoclonalAntibodies #MagneticSeparation #mRNA #vaccinedevelopment #immunotherapy #viralvectors #bioseparation #nucleicacids #DNA #cellseparation
-
-
Did you know that the majority of natural proteins contain at least one alpha helix? These structures play critical roles in folding, protein and DNA binding, membrane anchoring, and other essential biological processes.??? ?? With our Helicon platform, we’ve leveraged the unique capabilities of alpha helices to create a novel class of therapeutics. These stabilized helical peptides are capable of efficient cell entry and modulation of protein-protein and protein-DNA interactions — opening up a vast realm of possibilities to reach targets inaccessible to other kinds of medicines.?? ?? Learn more about Helicons here: https://lnkd.in/eWzFMkt9?? ?? #Biotechnology #Helicons #CreatingExtraordinaryMedicines???
-
Our recent publication in collaboration with X-Chem, Inc., Relay Therapeutics, and Google, showcases a large-scale approach to discovering and characterizing small-molecule ligands for the WD40 repeat (WDR) protein family-a promising but underexplored target class with over 350 members in the human genome. Through cloning, expressing, and purifying 100 distinct WD40 proteins, we established a comprehensive resource of protocols for protein production, structural characterization, and biochemical and cellular assays. Our pilot screen, leveraging DNA-encoded libraries and machine learning predictions, successfully identified first-in-class, drug-like ligands for 7 out of 16 screened WDR domains. Tip from the experts: Don’t miss the supplementary information, which includes an extensive dataset and toolkit-an enormous volume of work from SGC researchers that is now publicly available, enabling and empowering researchers worldwide to explore WDR proteins further. Read the full study here: https://lnkd.in/gvuixmsR #DrugDiscovery #OpenScience #WDRproteins
-
#Peptides and #DrugDiscovery – Part 3 In our previous post, we explored how Solid-Phase Peptide Synthesis revolutionized #peptide #drugdiscovery, though challenges remained. Fortunately, advances in recombinant DNA technology in the 1970s allowed researchers to start cloning genes and expressing peptides in various organisms, improving their resistance to biodegradation and enhancing their activity, which was increasingly tested by highly efficient screening technologies. This combined developments helped lead to the approval of the first synthetic peptide drugs, such as gonadotropin-releasing hormone (GnRH) analogs and somatostatin analogs, in the 1970s and 1980s, highlighting the therapeutic potential of peptides. What happened next? Stay tuned for our next post! Read our previous post here > https://lnkd.in/dkmVba_E #healthcareinnovation
-
-
Missed this opportunity to hear Dr. Victoria Conlin & Danny Leung present applications for intestinal #Organoids for #DrugDiscovery? You can now watch this webinar with STEMCELL Technologies on-demand, here ?? https://bit.ly/49wvFAA Discover applications of intestinal organoid cultures in: ?? Drug discovery, including how organoid-derived intestinal cell cultures can be applied to assess the toxicity of potential therapeutic compounds ?? Modeling barrier function #Intestine #GutResearch #DrugDevelopment
-
APP NOTE: The #VirD? Membrane Protein Microarray represents a groundbreaking platform for screening biologics against membrane proteins. The VirD technology consists of HSV-1 virions which are engineered to display membrane-embedded proteins of interest with native folding and function. Each engineered virion is individually cultured in human cells, purified, and printed onto glass slides to create VirD microarrays. In the app note, we describe how embedding functional, post-translationally modified receptors in the lipid envelope of viral particles allows VirD to preserve the native conformation of GPCRs, enhancing receptor functionality and data accuracy. This method also eliminates interference from endogenous proteins, often seen in cell-based systems, and provides unbiased screening for targets, even when the downstream signaling pathways are unknown. View and download PDF: https://lnkd.in/gpMsfnqw #targetid #proteomics #proteome #proteins #membraneproteins
-
Check out our new PPI inhibitor screen
Vipergen now releases: DELs in Cells - PPI Inhibitor Direct The?DELs in Cells – PPI Inhibitor Direct?service provides an offering for directly discovering protein-protein interaction inhibitors for your target proteins. With this service, we utilize our unique technology for screening in living cells in a duplex format, hereby enabling direct screening for PPI inhibitors in DNA encoded libraries. The DELs in Cells – PPI Inhibitor Direct service provides an excellent choice for targets, where inhibition of protein-protein interaction is the preferred pharmaceutical mode of action. Contact us if you would like to know more - or see our website at https://lnkd.in/dgwQmfUG to get an introduction. Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell.
-
Scientific Leader ? Precision Medicine ? Multi-Omics ? Mass Spec ? Bioinformatics
??Expanding our toolbox to deal with disease related proteins A recent preprint by Kheewoong?Baek et al. provides a comprehensive blueprint for robust and scalable identification of drug-induced protein degradation. This paves the way for novel therapeutic strategies through targeted protein degradation. Mass spectrometry-based targeted protein degradation is revolutionizing drug discovery by expanding the druggable proteome as it allows for identification of compounds that degrade disease-causing proteins. With this approach researchers can develop strategies to deal with previously undruggable targets, opening new avenues for treatment and enhancing the efficacy of existing therapies. Thanks to the teams around Eric Fischer, Katherine Donovan, Nathanael Gray for this amazing research! https://lnkd.in/g8_AiNuV #TPD #Chemoproteomics #DrugDiscovery #ProteinDegradation #MolecularGlues #timsTOF #StayCurious
-
We had fun unboxing the latest addition to the Custom Biologics "family": our brand new biolayer interferometry instrument from Gator Bio! ?? Considered the next generation in BLI analysis, it enables us to perform label-free, real-time measurements of biomolecular interactions, such as: - Antibody titer determination - Yes/no binding to target antigen - Isotyping - Epitope binning - Cross-reactivity testing - Affinity determination - Small molecule measurements - Off-rate ranking - Binding rates determination - Protein expression optimization Please join us in welcoming our new equipment to the lab ?? #BLI #biolayerinterferometry #bioassays
